A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not limited to lung cancer, melanoma, renal cell carcinoma, and Hodgki...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahoney, Kathleen M., Shukla, Sachet A., Patsoukis, Nikolaos, Chaudhri, Apoorvi, Browne, Edward P., Arazi, Arnon, Eisenhaure, Thomas M., Pendergraft, William F., Hua, Ping, Pham, Hung C., Bu, Xia, Zhu, Baogong, Hacohen, Nir, Fritsch, Edward F., Boussiotis, Vassiliki A., Wu, Catherine J., Freeman, Gordon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426808/
https://www.ncbi.nlm.nih.gov/pubmed/30564891
http://dx.doi.org/10.1007/s00262-018-2282-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426808/
https://www.ncbi.nlm.nih.gov/pubmed/30564891
http://dx.doi.org/10.1007/s00262-018-2282-1

Ejemplares similares